The KNG1 Polyclonal Antibody (PACO27837) is a valuable tool for researchers studying the kininogen-1 (KNG1) protein, which is involved in the regulation of blood coagulation and inflammation. This antibody, produced in rabbits, demonstrates high reactivity with human samples and is optimized for Western blot applications.KNG1, also known as high molecular weight kininogen, plays a crucial role in the kallikrein-kinin system, which is linked to various physiological and pathological processes. By targeting the KNG1 protein, researchers can investigate its functions in blood clotting, inflammation, and vascular permeability.
The KNG1 Polyclonal Antibody is ideal for studies in hemostasis, thrombosis, and vascular biology, providing valuable insights into the mechanisms underlying these processes. Its specificity and sensitivity make it a reliable tool for exploring the role of KNG1 in health and disease, offering new possibilities for therapeutic interventions targeting the kallikrein-kinin system.
Kininogens are inhibitors of thiol proteases; (2) HMW-kininogen plays an important role in blood coagulation by helping to position optimally prekallikrein and factor XI next to factor XII; (3) HMW-kininogen inhibits the thrombin- and plasmin-induced aggregation of thrombocytes; (4) the active peptide bradykinin that is released from HMW-kininogen shows a variety of physiological effects: (4A) influence in smooth muscle contraction, (4B) induction of hypotension, (4C) natriuresis and diuresis, (4D) decrease in blood glucose level, (4E) it is a mediator of inflammation and causes (4E1) increase in vascular permeability, (4E2) stimulation of nociceptors (4E3) release of other mediators of inflammation (e.g. prostaglandins), (4F) it has a cardioprotective effect (directly via bradykinin action, indirectly via endothelium-derived relaxing factor action); (5) LMW-kininogen inhibits the aggregation of thrombocytes; (6) LMW-kininogen is in contrast to HMW-kininogen not involved in blood clotting.
Function: 1 Kininogens are inhibitors of thiol proteases; (2) HMW-kininogen plays an important role in blood coagulation by helping to position optimally prekallikrein and factor XI next to factor XII; (3) HMW-kininogen inhibits the thrombin- and plasmin-induced aggregation of thrombocytes; (4) the active peptide bradykinin that is released from HMW-kininogen shows a variety of physiological effects: (4A) influence in smooth muscle contraction, (4B) induction of hypotension, (4C) natriuresis and diuresis, (4D) decrease in blood glucose level, (4E) it is a mediator of inflammation and causes (4E1) increase in vascular permeability, (4E2) stimulation of nociceptors (4E3) release of other mediators of inflammation (e.g. prostaglandins), (4F) it has a cardioprotective effect (directly via bradykinin action, indirectly via endothelium-derived relaxing factor action); (5) LMW-kininogen inhibits the aggregation of thrombocytes; (6) LMW-kininogen is in contrast to HMW-kininogen not involved in blood clotting.
UniProt Protein Details:
NCBI Summary:
precursor protein of kinin which is found in plasma; cysteine protease inhibitor and a major acute phase reactant [RGD, Feb 2006]